C17H21N3O3
Neat
315.37
313369-25-4; (6bR, 10aS)-Ethyl 3-methyl-2-oxo-2, 3, 6b, 7, 10, 10a-hexahydro-1H-pyrido[3', 4':4, 5]pyrrolo[1, 2, 3-de]quinoxaline-8(9H)-carboxylate; MFCD30730051; 313544-76-2; Ethyl (10R, 15S)-4-methyl-3-oxo-1, 4, 12-triazatetracyclo[7.6.1.05, 16.010, 15]hexadeca-5, 7, 9(16)-triene-12-carboxylate; ethyl (6bR, 10aS)-3-methyl-2-oxo-2, 3, 6b, 9, 10, 10a-hexahydro-1H-pyrido[3', 4':4, 5]pyrrolo[1, 2, 3-de]quinoxaline-8(7H)-carboxylate; LX4U5ED8K4; 5PDA2934BA; SCHEMBL3310339; SCHEMBL30011871; FAGHUWIRBRMPCV-STQMWFEESA-N; 1H-Pyrido[3', 4':4, 5]pyrrolo[1, 2, 3-de]quinoxaline-8(7H)-carboxylic acid, 2, 3, 6b, 9, 10, 10a-hexahydro-3-methyl-2-oxo-, ethyl ester, (6bR, 10aS)-; AKOS030228704; Lumateperone Impurity N7and enantiomer; DS-3445; SY266253; CS-0128208; C74607; (6bR, 10aS)-Ethyl3-methyl-2-oxo-2, 3, 6b, 7, 10, 10a-hexahydro-1H-pyrido[3', 4':4, 5]pyrrolo[1, 2, 3-de]quinoxaline-8(9H)-carboxylate; 1H-Pyrido[3', 4':4, 5]pyrrolo[1, 2, 3-de]quinoxaline-8(7H)-carboxylic acid, 2, 3, 6b, 9, 10, 10a-hexahydro-3-methyl-2-oxo-, ethyl ester, (6bR and 10aS)-rel-
ethyl (10R, 15S)-4-methyl-3-oxo-1, 4, 12-triazatetracyclo[7.6.1.05, 16.010, 15]hexadeca-5, 7 and 9(16)-triene-12-carboxylate
InChI=1S/C17H21N3O3/c1-3-23-17(22)19-8-7-13-12(9-19)11-5-4-6-14-16(11)20(13)10-15(21)18(14)2/h4-6,12-13H,3,7-10H2,1-2H3/t12-,13-/m0/s1